跳至主要内容
临床试验/ACTRN12623001356651
ACTRN12623001356651尚未招募2 期

Feasibility of Pregabalin for the treatment of CANVAS associated chronic cough

Richard Roxburgh0 个研究点目标入组 18 人开始时间: 2023年12月21日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Participants with neurological symptoms attributable to RFC1 pathology (neuropathy, vestibular failure, ataxia)
  • Positive RFC1 genetic test (either biallelic pathological expansion or pathological expansion and pathological variant).
  • > 1 year of chronic cough
  • 18 years and over
  • Can give informed consent.
  • Has access to a smart phone.

排除标准

  • History of cancer (other than skin squamous cell carcinoma (SSC) or basal cell carcinoma (BCC)).
  • History of severe renal impairment (glomerular filtration rate (GFR) < 30)
  • History of intolerance to pregabalin
  • Pregnancy*/breastfeeding.
  • Active respiratory disease.
  • Current or recently quit (< 6 months) smokers.
  • Angiotensin Converting Enzyme (ACE) inhibitor use.
  • Productive cough.
  • Use of any pregabalin, gabapentin within 3 months of baseline visit
  • Comorbid medical condition which, in the opinion of the Principal Investigator (PI) will either confound the outcome of the study, or place the participant at risk
  • Blood test abnormalities at screening indicating severe liver or kidney dysfunction

研究者

发起方
Richard Roxburgh

相似试验